文献速递艾滋病与性传播感染病毒性肝炎

美国感染与未感染HIV人群丙肝直接抗病毒治疗级联及治疗启动障碍

Direct-Acting Antiviral Hepatitis C Treatment Cascade and Barriers to Treatment Initiation Among US Men and Women With and Without HIV.
PubMed 文献 · J Infect Dis · 2021-01-01

该研究利用女性机构间HIV研究和多中心AIDS队列研究数据,构建2015-2018年丙肝治疗级联,纳入治疗 eligible 女性323例、男性92例。HIV阳性者级联各环节达标率高于HIV阴性者,黑人男性和物质使用者治疗率较低,未治疗男性临床障碍普遍。

要点

  • HIV阳性女性治疗启动率39% vs HIV阴性23%,SVR率21% vs 12%。
  • 黑人男性和物质使用者接受治疗较少。
  • 未治疗男性中临床障碍普遍(53%)。

核心结论

  • HIV照护可能促进HCV治疗链接和障碍导航,HIV阴性者、黑人男性和物质使用者可能需要额外支持。

研究设计与样本

  • 利用女性机构间HIV研究(6次访视,2015-2018年,n=2447)和多中心AIDS队列研究(1次访视,2015-2018年,n=2221)构建HCV治疗级联。
  • 级联纳入治疗 eligible 个体(HCV RNA阳性或报告使用DAA)。
  • 调查收集自我报告的临床、患者、系统和财务/保险障碍。

主要发现

  • 治疗 eligible 女性323例、男性92例,多数为HIV阳性(77%/70%),黑人占69%/63%。
  • HIV阳性女性比HIV阴性女性更可能达到级联结局(启动治疗39% vs 23%,SVR 21% vs 12%),男性有类似差异。
  • 黑人男性和物质使用者接受治疗较少。
  • 启动治疗的女性(vs 未启动)报告更少的患者障碍(14%/33%)。
  • 未治疗男性中临床障碍普遍(53%)。

临床怎么用

  • HIV照护环境可能有助于HCV治疗链接和障碍导航。
  • 对HIV阴性个体、黑人男性和物质使用者应考虑额外支持以促进HCV治疗启动。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with HIV are disproportionately coinfected with hepatitis C virus (HCV) and experience accelerated liver-related mortality. Direct-acting antivirals (DAAs) yield high sustained virologic response (SVR) rates, but uptake is suboptimal. This study characterizes the DAA-era HCV treatment cascade and barriers among US men and women with or at risk for HIV. METHODS: We constructed HCV treatment cascades using the Women's Interagency HIV Study (women, 6 visits, 2015-2018, n = 2447) and Multicenter AIDS Cohort Study (men, 1 visit, 2015-2018, n = 2221). Cascades included treatment-eligible individuals (ie, HCV RNA-positive or reported DAAs). Surveys captured self-reported clinical (eg, CD4), patient (eg, missed visits), system (eg, appointment access), and financial/insurance barriers. RESULTS: Of 323/92 (women/men) treatment eligible, most had HIV (77%/70%); 69%/63% were black. HIV-positive women were more likely to attain cascade outcomes than HIV-negative women (39% vs 23% initiated, 21% vs 12% SVR); similar discrepancies were noted for men. Black men and substance users were treated less often. Women initiating treatment (vs not) reported fewer patient barriers (14%/33%). Among men not treated, clinical barriers were prevalent (53%). CONCLUSIONS: HIV care may facilitate HCV treatment linkage and barrier navigation. HIV-negative individuals, black men, and substance users may need additional support. CLINICAL TRIALS REGISTRATION: NCT00000797 (Women's Interagency HIV Study); NCT00046280 (Multicenter AIDS Cohort Study).

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Haley DF, Edmonds A, Ramirez C, et al. Direct-Acting Antiviral Hepatitis C Treatment Cascade and Barriers to Treatment Initiation Among US Men and Women With and Without HIV. J Infect Dis. 2021. PMID: 33141170. doi:10.1093/infdis/jiaa686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。